Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lipitor Generics Could Come 15 Months Earlier Than Anticipated After Patent Deemed Invalid

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer says “technical defect” in patent could be corrected with U.S. Patent and Trademark Office.

You may also be interested in...



Pfizer Wins Lipitor Reversal

Patent office's decision blocks generic atorvastatin until 2010.

Pfizer Wins Lipitor Reversal

Patent office's decision blocks generic atorvastatin until 2010.

Pfizer Terminates Torcetrapib Program

Company will investigate whether an increased risk of mortality is a class effect of CETP inhibitors.

Related Content

Topics

UsernamePublicRestriction

Register

OM017301

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel